Sangamo Therapeutics, Inc., a leading genomic medicine company, has reported promising updated data from the Phase 1/2 STAAR study. This study explores the efficacy of isaralgagene civaparvovec (ST-920) as a treatment for Fabry disease. The analysis, which reflects data up to September 12, 2024,
Allarity Therapeutics, Inc. has announced the expansion of their Phase 2 clinical trial for stenoparib, a dual PARP/Wnt pathway inhibitor, aimed at treating advanced ovarian cancer. Their recent decision seeks to accelerate the drug's clinical development and work towards FDA regulatory
Clinical trials are fundamental to the development of new medical treatments and the advancement of healthcare. However, enrolling and retaining participants in these trials has been a persistent challenge over the years. The perceived difficulty of involvement, alongside high dropout rates, can
The 21st century has seen the pharmaceutical industry face mounting challenges such as escalating competition and pricing pressures. Consequently, developers and manufacturers are pioneering innovative strategies to differentiate their products and instill value, particularly in the saturated
The human gut microbiome plays a crucial role in overall health, influencing everything from digestion to immune function. Recent advancements in proteo-genomics have provided unprecedented insights into the complex interactions within the gut microbiome. A groundbreaking study has utilized
In a groundbreaking development, the recent trials of a drug developed by Ireland-based psychedelics biotech company GH Research have showcased its potential in treating treatment-resistant depression. The mid-stage clinical trial, comprising 81 participants, revealed a significant reduction in
